(19)
(11) EP 4 469 080 A2

(12)

(88) Date of publication A3:
31.08.2023

(43) Date of publication:
04.12.2024 Bulletin 2024/49

(21) Application number: 23708311.8

(22) Date of filing: 27.01.2023
(51) International Patent Classification (IPC): 
A61K 39/12(2006.01)
A61P 31/14(2006.01)
A61K 39/215(2006.01)
C07K 14/005(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 39/12; A61P 31/14; C07K 14/005; C12N 2770/20022; C12N 2770/20034
(86) International application number:
PCT/US2023/011791
(87) International publication number:
WO 2023/147092 (03.08.2023 Gazette 2023/31)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 28.01.2022 US 202263304560 P
05.07.2022 US 202263358523 P
09.08.2022 US 202263396580 P
18.01.2023 US 202363480375 P

(71) Applicants:
  • BioNTech SE
    55131 Mainz (DE)
  • Pfizer Inc.
    New York, NY 10001-2192 (US)

(72) Inventors:
  • CHE, Ye
    Groton, Connecticut 06340 (US)
  • SWANSON, Kena Anne
    Middletown Road Pearl River, New York 10965 (US)

(74) Representative: Schnappauf, Georg 
ZSP Patentanwälte PartG mbB Hansastraße 32
80686 München
80686 München (DE)

   


(54) CORONAVIRUS VACCINE